T1	Participants 22 124	finasteride-treated subjects and male pseudohermaphrodites with inherited 5 alpha-reductase deficiency
T2	Participants 137 258	Male pseudohermaphrodites (MPHs) with inherited 5 alpha-reductase deficiency and decreased dihydrotestosterone production
T3	Participants 711 831	men with benign prostatic hyperplasia who were administered varying doses of the 5 alpha-reductase inhibitor finasteride
